{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:54:09Z","timestamp":1791500049045,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","award":["17K09651"],"award-info":[{"award-number":["17K09651"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10147-020-01755-1","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T06:02:22Z","timestamp":1596261742000},"page":"1928-1935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Short hydration with 20\u00a0mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9653-8424","authenticated-orcid":false,"given":"Tetsunari","family":"Hase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Yogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyofumi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,1]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","volume":"26","author":"NSCLC Meta-Analyses Collaborative Group","year":"2008","unstructured":"NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617\u20134625","journal-title":"J Clin Oncol"},{"key":"1755_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1054\/bjoc.2000.1164","volume":"83","author":"JL Pujol","year":"2000","unstructured":"Pujol JL, Carestia L, Daur\u00e8s JP (2000) Is there a case for cisplatin in the treatment of small-cell lung cancer? a meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83:8\u201315","journal-title":"Br J Cancer"},{"key":"1755_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/jnci\/djk196","volume":"99","author":"A Ardizzoni","year":"2007","unstructured":"Ardizzoni A, Boni L, Tiseo M et al (2007) Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847\u2013857","journal-title":"J Natl Cancer Inst"},{"key":"1755_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85\u201391","journal-title":"N Engl J Med"},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 26:3552\u20133559","journal-title":"J Clin Oncol"},{"key":"1755_CR6","first-page":"551","volume":"213","author":"D Dobyan","year":"1980","unstructured":"Dobyan D, Levi J, Jacobs C et al (1980) Mechanism of cis-platinum nephrotoxicity: II morphologic observations. J Pharmacol Exp Ther 213:551\u2013556","journal-title":"J Pharmacol Exp Ther"},{"key":"1755_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","volume":"23","author":"I Arany","year":"2003","unstructured":"Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Sem Nephrol 23:460\u2013464","journal-title":"Sem Nephrol"},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994\u20131007","journal-title":"Kidney Int"},{"key":"1755_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/jjco\/hyr145","volume":"41","author":"K Yamada","year":"2011","unstructured":"Yamada K, Yoshida T, Zaizen Y et al (2011) Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey. Jpn J Clin Oncol 41:1308\u20131311","journal-title":"Jpn J Clin Oncol"},{"key":"1755_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1177\/106002808501900505","volume":"19","author":"R Finley","year":"1985","unstructured":"Finley R, Fortner C, Grove W (1985) Cisplatin nephrotoxicity: a summary of preventative interventions. Drug Intell Clin Pharm 19:362\u2013367","journal-title":"Drug Intell Clin Pharm"},{"key":"1755_CR11","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2013the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","volume":"10","author":"M Saito","year":"2009","unstructured":"Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115\u2013124","journal-title":"Lancet Oncol"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2354.2011.01284.x","volume":"21","author":"N Furukawa","year":"2012","unstructured":"Furukawa N, Kawaguchi R, Kobayashi H (2012) Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care 21:436\u2013441","journal-title":"Eur J Cancer Care"},{"key":"1755_CR14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/jjco\/hyt122","volume":"43","author":"H Horinouchi","year":"2013","unstructured":"Horinouchi H, Kubota K, Itani H et al (2013) Short hydration in chemotherapy containing cisplatin (\u226575 mg\/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43:1105\u20131109","journal-title":"Jpn J Clin Oncol"},{"key":"1755_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/jjco\/hyt128","volume":"43","author":"K Hotta","year":"2013","unstructured":"Hotta K, Takigawa N, Hisamoto-Sato A et al (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002. Jpn J Clin Oncol 43:1115\u20131123","journal-title":"Jpn J Clin Oncol"},{"key":"1755_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/030089160709300205","volume":"93","author":"M Tiseo","year":"2007","unstructured":"Tiseo M, Martelli O, Mancuso A et al (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93:138\u2013144","journal-title":"Tumori"},{"key":"1755_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10147-015-0860-1","volume":"21","author":"K Ninomiya","year":"2016","unstructured":"Ninomiya K, Hotta K, Hisamoto-Sato A et al (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21:81\u201387","journal-title":"Int J Clin Oncol"},{"key":"1755_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/1120009X.1990.11738971","volume":"2","author":"A Sobrero","year":"1990","unstructured":"Sobrero A, Guglielmi A, Aschele C et al (1990) Current strategies to reduce cisplatin toxicity. J Chemother 2:3\u20137","journal-title":"J Chemother"},{"key":"1755_CR19","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ejca.2008.08.005","volume":"44","author":"L Bodnar","year":"2008","unstructured":"Bodnar L, Wcislo G, Gasowska-Bodnar A et al (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608\u20132614","journal-title":"Eur J Cancer"},{"key":"1755_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/bjc.1986.147","volume":"54","author":"J Willox","year":"1986","unstructured":"Willox J, McAllister E, Sangster G, Kaye S (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54:19\u201323","journal-title":"Br J Cancer"},{"key":"1755_CR21","doi-asserted-by":"publisher","first-page":"xi103","DOI":"10.1016\/S0923-7534(20)32268-7","volume":"23","author":"T Yoshida","year":"2012","unstructured":"Yoshida T, Niho S, Toda M et al (2012) Protective effect of magnesium preloading on nephrotoxicity caused by cisplatin (over 60 MG\/M2) in patients with thoracic malignancy. Ann Oncol 23:xi103","journal-title":"Ann Oncol"},{"key":"1755_CR22","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/emj.19.4.288","volume":"19","author":"P Kaye","year":"2002","unstructured":"Kaye P, O\u2019Sullivan I (2002) The role of magnesium in the emergency department. Emerg Med J 19:288","journal-title":"Emerg Med J"},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"e101902","DOI":"10.1371\/journal.pone.0101902","volume":"9","author":"Y Kidera","year":"2014","unstructured":"Kidera Y, Kawakami H, Sakiyama T et al (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS ONE 9:e101902","journal-title":"PLoS ONE"},{"key":"1755_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/jjco\/hyt020","volume":"43","author":"S Niho","year":"2013","unstructured":"Niho S, Yamanaka T, Umemura S et al (2013) Renal toxicity caused by brand-name versus generic cisplatin: a comparative analysis. Jpn J Clin Oncol 43:390\u2013395","journal-title":"Jpn J Clin Oncol"},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982\u2013992","journal-title":"Am J Kidney Dis"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MAJ.0b013e31812dfe1e","volume":"334","author":"X Yao","year":"2007","unstructured":"Yao X, Panichpisal K, Kurtzman N et al (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115","journal-title":"Am J Med Sci"},{"key":"1755_CR27","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1002\/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO;2-C","volume":"39","author":"E Cvitkovic","year":"1977","unstructured":"Cvitkovic E, Spaulding J, Bethune V et al (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357\u20131361","journal-title":"Cancer"},{"key":"1755_CR28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J","volume":"39","author":"D Hayes","year":"1977","unstructured":"Hayes D, Cvitkovic E, Golbey R et al (1977) High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372\u20131381","journal-title":"Cancer"},{"key":"1755_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/ctrv.1999.0097","volume":"25","author":"H Lajer","year":"1999","unstructured":"Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25:47\u201358","journal-title":"Cancer Treat Rev"},{"key":"1755_CR30","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/ndt\/gfs268","volume":"28","author":"S Alves","year":"2013","unstructured":"Alves S, Tomasi C, Constantino L et al (2013) Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 28:910\u2013916","journal-title":"Nephrol Dial Transplant"},{"key":"1755_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00000421-199208000-00016","volume":"15","author":"M Martin","year":"1992","unstructured":"Martin M, Diaz-Rubio E, Casado A et al (1992) Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. results of a controlled trial. Am J Clin Oncol 15:348\u2013351","journal-title":"Am J Clin Oncol"},{"key":"1755_CR32","doi-asserted-by":"publisher","first-page":"e000288","DOI":"10.1136\/esmoopen-2017-000288","volume":"3","author":"H Horinouchi","year":"2018","unstructured":"Horinouchi H, Kubota K, Miyanaga A et al (2018) Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. ESMO Open 3:e000288","journal-title":"ESMO Open"},{"key":"1755_CR33","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1517\/14740338.2011.606213","volume":"11","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M et al (2012) Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies. Exp Opin Drug Saf 11:S9\u201319","journal-title":"Exp Opin Drug Saf"},{"key":"1755_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","volume":"16","author":"N Thatcher","year":"2015","unstructured":"Thatcher N, Hirsch FR, Luft AV et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763\u2013774","journal-title":"Lancet Oncol"},{"key":"1755_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/annonc\/mdl377","volume":"18","author":"Y Ohe","year":"2007","unstructured":"Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 18:317\u2013323","journal-title":"Ann Oncol"},{"key":"1755_CR36","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/annonc\/mdv190","volume":"26","author":"K Kubota","year":"2015","unstructured":"Kubota K, Sakai H, Katakami N et al (2015) A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 26:1401\u20131408","journal-title":"Ann Oncol"},{"key":"1755_CR37","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2019.37.15_suppl.8501","volume":"37","author":"H Kenmotsu","year":"2019","unstructured":"Kenmotsu H, Yamamoto N, Yamanaka T et al (2019) Randomized phase III study of pemetrexed\/cisplatin (Pem\/Cis) versus vinorelbine \/cisplatin (Vnr\/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): the JIPANG study. J Clin Oncol 37:8501\u20138501","journal-title":"J Clin Oncol"},{"key":"1755_CR38","doi-asserted-by":"publisher","first-page":"14721","DOI":"10.1074\/jbc.273.24.14721","volume":"273","author":"A Ivanov","year":"1998","unstructured":"Ivanov A, Christodoulou J, Parkinson J et al (1998) Cisplatin binding sites on human albumin. J Biol Chem 273:14721\u201314730","journal-title":"J Biol Chem"},{"key":"1755_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/BF00451649","volume":"23","author":"Y Sasaki","year":"1989","unstructured":"Sasaki Y, Tamura T, Eguchi K et al (1989) Pharmacokinetics of (glycolato-0,0\u20320, diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243\u2013246","journal-title":"Cancer Chemother Pharmacol"},{"key":"1755_CR40","first-page":"609","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncology 22:609\u2013619","journal-title":"Oncology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01755-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T20:13:44Z","timestamp":1627762424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01755-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01755-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,1]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compilance with ethical standards"}},{"value":"T. Hase received honoraria from Chugai Pharmaceutical Co., Ono Pharmaceutical Co., AstraZeneca, Bristol-Myers Squibb K.K., Pfizer Inc., Boehringer Ingelheim, and Eli Lilly Japan K.K. and research funding from Boehringer Ingelheim. Y. Hasegawa received grants from Boehringer Ingelheim, AstraZeneca, Eli Lilly Japan K.K., Ono Pharmaceutical Co., Bristol-Myers Squibb K.K., Taiho Pharmaceutical Co., Novartis Pharma K. K., and Chugai-Pharmaceutical Co. and honoraria from Boehringer Ingelheim, MSD K.K., AstraZeneca, Pfizer Inc., and Chugai-Pharmaceutical Co. M. Sato received a research funding from Pfizer Inc. All grants were paid to Nagoya University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}